What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Brain Atrophy/Neurodegeneration: A Neuropathologist Perspective
Brain Volume Change: Under Multiple Influences
Brain Atrophy/Neurodegeneration: A Clinical Perspective
Pathological Causes of Brain Atrophy in MS
Mechanisms of Neurodegeneration in MS
Correlation Between Focal and Diffuse Pathological Changes
Detection of Brain Atrophy in MS Patients Using Imaging Techniques
Common Measures for Whole Brain and Regional Brain Atrophy
Brain Atrophy Is Related to Long-Term Disability in RRMS
GM and WM Volume Changes in Early RRMS
Pseudoatrophy After DMT Treatment
Effect of BRACE Therapies On Brain Volume Loss
Brain Volume Loss Outcomes: Results From the AFFIRM Trial
Alemtuzumab Brain Volume Loss Through Year 5
Teriflunomide Reduced Annual Brain Volume Loss Over 2 years in the TEMSO Study*
Reduction in PBVC With DMF: Significant in DEFINE But Not CONFIRM
ENDORSE Extension Trial Results
Fingolimod: Summary of Brain Volume Loss Data in FREEDOMS, FREEDOMS II, and TRANSFORMS
Sustained Reduction in Brain Volume Loss Over 4 Years
PREFERMS: Phase 4 Patient Outcomes on Fingolimod versus Platform Injectable DMTs
Contribution of Individual Components of NEDA-4 on Proportion of Patients Achieving NEDA
Predictive Value of NEDA for Disease Outcomes Over 6 Years
Types of Inflammation in MS
Evidence for Direct CNS Effects
Adding Brain Volume Loss to the Modified Rio Score System
Persistent MRI Lesion Activity and Brain Volume Loss as Predictors of Long-Term Disability Progression
Conclusions
Abbreviations
Abbreviations (cont)